top of page

Videnskabelige studier om mRNA

The Rise of mRNA COVID-19 Vaccine-Associated Myocarditis and Its Implications on the Future Use of This New Vaccine Platform

Cardiac

The very low risk of myocarditis and pericarditis after mRNA COVID-19 vaccination should not discourage vaccination

Cardiac

Torsades de Pointes Following Vaccination for COVID-19

Cardiac

Transient Myopericarditis Following Vaccination for COVID-19

Cardiac

Myocarditis should be consider in those with a troponin rise and unobstructed arteries following Pfizer vaccination

Cardiac

Myocarditis Temporally Associated With COVID-19 Vaccination

Cardiac

Myocarditis With COVID-19 mRNA Vaccines

Cardiac

Myocarditis, Pericarditis and Cardiomyopathy After COVID-19 Vaccination

Cardiac

Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine, A Case Report

Cardiac

Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea, Case Report Focusing on Histopathological Findings

Cardiac

Myokarditis nach mRNA-Impfung

Cardiac

Myopericarditis after administration of the Comirnaty© vaccine against SARS-CoV-2

Cardiac

Myopericarditis After COVID-19 Booster Dose Vaccination

Cardiac

Myopericarditis After COVID-19 mRNA Vaccination

Cardiac

Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age

Cardiac

Myopericarditis After mRNA COVID-19 Vaccine in a Patient With Recent History of COVID-19

Cardiac

Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents

Cardiac

Myopericarditis following both BNT162b2 and NVX-CoV2373

Cardiac

Myopericarditis following COVID-19 vaccination in adolescent triplets

Cardiac

Myopericarditis following SARS-CoV-2 mRNA vaccine, the role of cardiac biomarkers and multimodality imaging

Cardiac
bottom of page